ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO810

Diploid Gene Deletion of Transient Receptor Potential Canonical 1 (TRPC1) Channel Produces Metabolic Syndrome (MetS) but Prevents Further Liver Steatosis and Dyslipidemia Induced by a High-Fat Diet (HFD)

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Mahmood, Muhammad Bilal, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
  • Eby, Bonnie, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
  • Barron, Lindsay J., University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
  • Lau, Alexander, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
  • Pantalia, Meghan M., Columbia University, New York, New York, United States
  • Khan, Usman A., University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
  • Skaggs, Chris D., OU Medical Center, Moore, Oklahoma, United States
  • Lau, Kai, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
Background

There is growing evidence for the role of TRPC1 in regulating glucose & lipid metabolism. Secretion of insulin, leptin & adiponectin is sensitive to cell free Ca. TRPC1 may mediate the effects of leptin in anorexigenic hypothalamic neurons. TRPC1 iwas found low in diabetes & we recently found hyperglycemia in null mice. We tested if TRPC1 deficiency produces MetS & if 45% HFD x 3 mon aggravates it.

Methods

In age-matched TRPC1 +/+. +/-, & -/- mice, we measured glucose & lipids using standard methods & insulin, leptin, & adiponectin by mouse ELISA. We did glucose tolerance test (GTT) by IP glucose (2 mg/kg) after 13 h fast.

Results

From 4-30 week, null mice ate & weighed more than +/- & wt. At 4 mon, HOMA-insulin resistance (IR) was up 60% & HOMA β down 40%. By 12 mon, HOMA-IR was up 8 fold. At 7 mon, by GTT, both TRPC1 +/- & -/- mice were diabetic. In null, adiponectin was down 11% but leptin up 77%. At 2 mon, total cholesterol was 85% hgher in null, their liver 36% heavier, & triglyceride content (TGC) 47% higher. Liver echogenicity was up by 50-150% at 7, 11, & 22 mon, confirmed by 140% higher liver TGC. At 12 mon, only null mice had hyperlipidemia (cholesterol up 30%, LDL up 60%, & TG up 200%). In +/- & wt, lipids, liver density at 12 & 19 mon, & liver TGC at 19 mon were all normal. Fasting glucose was high only in null from 1 through 16 mon). Thus on a normal fat diet (NFD), 1 wt allele prevented hyperphagia, obesity, MetS & hepatic steatosis. As expected, HFD vs NFD stimulated leptin & insulin, similarly in all 3 genotypes without altering adiponectin. Unlike NFD, HFD increased liver density in +/- & wt, but not in null. HFD induced the highest HOMA-IR in wt (3.1 vs 1.3 x in +/-) & the largest liver TGC hike in wt (3.3 vs 1.6 x in null). During GTT, AUC for glucose vs time was the highest in wt vs null.

Conclusion

1. Diploid TRPC1 deletion produces hyperphagia, obesity & Met S, all resolvable by caloric restriction, implying hypothalamic resistance to leptin in null mice. 2. HFD raises the risks of dyslipidemia & hepatic steatosis, only in the presence of 1-2 wt alleles, as if deficiency would block the pathogenic Ca-CM-NFAT signaling pathway. 3. TRPC1 -/- is a good model to study MetS.

Funding

  • NIDDK Support